Gliptus Plus 50/850 Mg

Gliptus Plus 50/850 Mg

Description:

Gliptus Plus 50/850 mg is an oral antidiabetic prescription medicine used for the management of type 2 diabetes mellitus in adults. It combines vildagliptin, a DPP-4 inhibitor, with metformin hydrochloride, a biguanide, in one tablet to improve blood glucose control when diet and exercise alone are not sufficient. This fixed-dose combination from Eva Pharma helps lower fasting and post‑meal blood sugar, supports long‑term glycemic control, and reduces the risk of diabetes-related complications as part of a comprehensive diabetes care plan.

Indications:

• Type 2 diabetes mellitus in adults, particularly in patients insufficiently controlled on metformin alone.
• Type 2 diabetes mellitus in adults already treated with the combination of vildagliptin and metformin as separate tablets.
• Improvement of glycemic control (fasting plasma glucose and postprandial glucose).
• Reduction of elevated HbA1c levels as part of long‑term diabetes management.
• Adjunct to diet and exercise in overweight or obese adults with type 2 diabetes, when lifestyle measures alone are inadequate.

Active Ingredients / Key Components:

• Vildagliptin – 50 mg per tablet (dipeptidyl peptidase‑4 (DPP‑4) inhibitor).
• Metformin hydrochloride – 850 mg per tablet (biguanide oral antidiabetic agent).
• Other excipients: full list of inactive ingredients (tablet core and coating) is not available in the provided information; please refer to the official package leaflet for complete details.

Dosage & Administration / How to Use:

• Gliptus Plus 50/850 mg is for oral use only and must be taken exactly as prescribed by your physician.
• Typical adult dose: usually 1 tablet twice daily (morning and evening), or as directed by the treating doctor, based on previous therapy and blood glucose levels.
• Take the tablets with meals to reduce gastrointestinal side effects associated with metformin (such as nausea, abdominal discomfort, or diarrhea).
• Swallow the tablet whole with a glass of water; do not crush or chew unless your doctor or pharmacist specifically advises otherwise.
• Dosage adjustments: your doctor may adjust the dose depending on kidney function, liver status, blood glucose response, and tolerability. Do not change the dose or stop the medication without medical advice.
• If switching from separate vildagliptin and metformin tablets, your doctor will choose the closest equivalent dose of Gliptus Plus.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not take a double dose to make up for a missed tablet.
• Use in children and adolescents: safety and efficacy in patients under 18 years have not been established; not recommended unless specifically prescribed by a specialist.
• Always combine treatment with an appropriate diabetic diet, regular physical activity, and routine blood glucose monitoring.

Clinical Benefits:

• Provides dual mechanism of action by combining vildagliptin and metformin for more comprehensive blood glucose control.
• Helps lower fasting and postprandial blood sugar levels and improve overall HbA1c in adults with type 2 diabetes.
• Vildagliptin enhances incretin hormones, increasing glucose‑dependent insulin secretion and decreasing glucagon release.
• Metformin reduces hepatic glucose production (suppresses gluconeogenesis) and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle and adipose tissue.
• May support weight neutrality or modest weight reduction compared with some other antidiabetic agents, due to the metformin component.
• Once‑ or twice‑daily tablet regimen (as prescribed) can improve treatment adherence compared with taking separate vildagliptin and metformin tablets.
• By improving glycemic control, it helps reduce the risk of long‑term complications of diabetes such as neuropathy, nephropathy, retinopathy, and cardiovascular events when used as part of a comprehensive management plan.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to vildagliptin, metformin, or any of the excipients.
• Contraindicated in patients with severe renal impairment or end‑stage renal disease, and in conditions that may affect kidney function (e.g., severe dehydration, shock, severe infection).
• Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis, with or without coma.
• Use with caution in patients with liver impairment or a history of liver disease; vildagliptin has been associated with rare cases of hepatic dysfunction. Regular liver function monitoring may be required.
• Risk of lactic acidosis: metformin can rarely cause lactic acidosis, a serious metabolic complication, especially in patients with renal impairment, uncontrolled diabetes, prolonged fasting, excessive alcohol intake, dehydration, or severe infection. Symptoms include rapid breathing, abdominal pain, muscle cramps, severe weakness, and feeling cold. Seek urgent medical attention if suspected.
• Discontinue temporarily before and after radiologic studies with iodinated contrast media or major surgery, as advised by your doctor, due to increased risk of lactic acidosis.
• Use with caution in elderly patients; kidney function should be assessed regularly.
• May cause hypoglycemia when used in combination with other antidiabetic agents such as sulfonylureas or insulin; dose adjustments of concomitant therapy may be needed.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Alternative treatments may be preferred during pregnancy and lactation.
• Consult your doctor before use if you have heart failure, recent myocardial infarction, severe infection, respiratory failure, or conditions associated with reduced tissue oxygenation.
• Avoid excessive alcohol intake while taking this medicine due to increased risk of lactic acidosis.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; it is a prescription medicine that must be used under healthcare professional guidance.
• Keep out of reach of children.

Side Effects:

• Common side effects (usually mild and transient): nausea, vomiting, diarrhea, abdominal pain, loss of appetite, metallic taste (mainly due to metformin); headache, dizziness, mild upper respiratory symptoms.
• Less common side effects: peripheral edema, fatigue, constipation, mild skin reactions such as rash or itching.
• Hypoglycemia (low blood sugar) is uncommon when used alone but may occur more frequently if combined with sulfonylureas or insulin; symptoms include sweating, tremor, hunger, palpitations, confusion, or blurred vision.
• Rare but serious side effects: lactic acidosis (medical emergency), severe allergic reactions (angioedema, difficulty breathing, facial or throat swelling), liver dysfunction (including hepatitis, elevated liver enzymes, jaundice), and pancreatitis (severe abdominal pain radiating to the back, nausea, vomiting).
• Stop the medication and seek immediate medical attention if you experience signs of lactic acidosis, severe abdominal pain, yellowing of the skin or eyes, dark urine, or any symptoms of a serious allergic reaction.
• If any side effects persist, worsen, or you notice any unusual symptoms, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: Prescription oral antidiabetic medicine.
• Active ingredients: vildagliptin 50 mg + metformin hydrochloride 850 mg per tablet.
• Form: Tablet.
• Pack size: 30 tablets per pack (blister strips inside carton).
• Intended use: Adult type 2 diabetes mellitus management as adjunct to diet and exercise.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.